Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature.
BACKGROUND
Primary small cell carcinoma of the upper urinary tract (UUT-SCC) is an extremely uncommon disease. The current knowledge of these rare tumors is mainly based on case reports or small series.


METHODS
We reported two cases and performed a systematic literature search from 1970 to 2010 for articles on UUT-SCC. Overall, 40 patients with UUT-SCC were reviewed, a database was generated to analyze clinical characteristics, pathological features and therapy outcomes and to attempt in identifying prognostic factors.


RESULTS
For the 39 cases with available data, median age was 66.5 years and male-female ratio was 2:1. An Asian ethnic background was more common (59%). Surgery was the standard treatment given to all patients. In 67% of cases, SCC coexisted with another malignant component, including urothelial carcinoma in 62% of patients. Overall median survival was 15 months and the 1-, 2- and 3-year survival rates were 58.4%, 38.1% and 23.8%, respectively. Of all cases, 53.8% developed detectable metastasis in a median delay of 13 months. Pathological stage was the only significant prognostic factor found (p=0.01). Patients who received adjuvant chemotherapy seem to have a higher median survival comparatively to those who did not receive chemotherapy but this was not statistically significant (24 vs. 12 months, p=0.56).


CONCLUSIONS
UUT-SCC is an extremely rare tumor characterized by an aggressive clinical course. Local or distant metastases are frequent and survival is poor. Pathological stage appeared to be a prognostic factor for overall survival.
Department of Urology, CHRU Lille, Univ Lille Nord de France, France. adil-ouzzane@orange.fr
Adil
A
Ouzzane
Tarek P
TP
Ghoneim
Kazuma
K
Udo
Marie
M
Verhasselt-Crinquette
Philippe
P
Puech
Nacim
N
Betrouni
Morgan
M
Rouprêt
Arnauld
A
Villers
Xavier
X
Leroy
Pierre
P
Colin
D000368:Aged; D001707:Biopsy, Needle; D018288:Carcinoma, Small Cell / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D035583:Rare Diseases; D018570:Risk Assessment; D016019:Survival Analysis; D014516:Ureteral Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014523:Urethral Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014571:Urologic Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy